We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$558M
AUM Growth
+$54.7M
Cap. Flow
+$23.7M
Cap. Flow %
4.24%
Top 10 Hldgs %
57.55%
Holding
51
New
14
Increased
7
Reduced
11
Closed
13

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$33.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$15M
4
PCRX icon
Pacira BioSciences
PCRX
+$13.9M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$13.8M

Top Sells

Rank Stock Value
1
TXMD icon
TherapeuticsMD
TXMD
+$24.9M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$15.2M
3
RXDX
Ignyta, Inc.
RXDX
+$10.7M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$10.4M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 79.15%
2 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.99M 1.25%
255,400
-44,600
-15% -$1.33M
PTCT icon
27
CALL
PTC Therapeutics
PTCT
$5.64B
$4.77M 0.85%
+260,000
New +$3.5M
DVAX
28
DELISTED
Dynavax Technologies
DVAX
$4.2M 0.75%
+435,500
New +$2.83M
TVRD
29
PUT
Tvardi Therapeutics
TVRD
$19.7M
$4.18M 0.75%
+7,539
New +$4.78M
SAGE
30
PUT
DELISTED
Sage Therapeutics
SAGE
$4.11M 0.74%
51,600
-248,400
-83% -$18M
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.86M 0.69%
40,890
-3,049
-7% -$350K
MYOV
32
DELISTED
Myovant Sciences Ltd.
MYOV
$2.9M 0.52%
247,899
-159,660
-39% -$1.98M
CNXR
33
DELISTED
Connecture, Inc.
CNXR
$2.55M 0.46%
4,127,232
– –
IOVA icon
34
Iovance Biotherapeutics
IOVA
$1.82B
$1.24M 0.22%
+169,014
New +$1.07M
ARDM
35
DELISTED
Aradigm Corp Common Stock
ARDM
$835K 0.15%
637,279
– –
TVRD
36
Tvardi Therapeutics
TVRD
$19.7M
$761K 0.14%
+1,374
New +$872K
STRM
37
DELISTED
Streamline Health Solutions
STRM
$139K 0.02%
8,676
-1,431
-14% -$26.2K
FOLD
38
CALL
DELISTED
Amicus Therapeutics
FOLD
$125K 0.02%
+12,400
New +$99.8K
ALNY icon
39
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-250,000
Closed -$12.8M
AUPH icon
40
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-1,000,000
Closed -$7.34M
BPMC
41
DELISTED
Blueprint Medicines
BPMC
– –
-122,129
Closed -$4.88M
JAZZ icon
42
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-25,000
Closed -$3.63M
TXMD icon
43
TherapeuticsMD
TXMD
$23.5M
– –
-69,205
Closed -$24.9M
TRVN
44
DELISTED
Trevena, Inc.
TRVN
– –
-541
Closed -$1.24M
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-539,571
Closed -$10.4M
ACOR
46
CALL
DELISTED
Acorda Therapeutics
ACOR
– –
-667
Closed -$1.68M
ACOR
47
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-3,604
Closed -$9.08M
RDUS
48
PUT
DELISTED
Radius Health, Inc.
RDUS
– –
-50,000
Closed -$1.93M
FPRX
49
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-155,265
Closed -$5.61M
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-200,000
Closed -$15.2M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Great Point Partners held 51 positions worth $558M, up 11% from $504M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners deployed $23.7M of net new capital in Q2 2017, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ignyta, Inc., an estimated $10.7M trimmed.

  • Great Point Partners's largest Q2 2017 buy was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.
  • Great Point Partners added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $17M increase.
  • Great Point Partners's biggest Q2 2017 reduction was Ignyta, Inc., cutting an estimated $10.7M.
  • Great Point Partners fully exited TherapeuticsMD in Q2 2017, selling an estimated $24.9M.
  • Great Point Partners's ten largest holdings make up 58% of its $558M portfolio in Q2 2017.
  • Great Point Partners opened 14 new positions and closed 13 in Q2 2017.
  • Great Point Partners's portfolio value rose 11% quarter-over-quarter to $558M.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.